Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
27 Leser
Artikel bewerten:
(0)

Global Infectious Disease Molecular Diagnostics Market 2015 - Business and Technological Trends in Major Markets

DUBLIN, Aug. 13, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/vbd2sd/2015_global) has announced the addition of the "2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies and Competitive Landscape" report to their offering.

This new seven-country study contains 1,265 pages, 191 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years.

Report Highlights

  • Business and technological trends in major markets
  • Five-year test volume and sales forecasts
  • Market shares of leading competitors
  • Feature comparison of major analyzers
  • Strategic profiles of leading market players and start-up firms developing innovative products
  • Specific product and business opportunities for instrument and consumable suppliers.

Rationale

The infectious disease molecular diagnostics market is one of the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the infectious disease molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Companies Mentioned

  • Abbott
  • Affymetrix
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Biotest
  • Cepheid
  • CellMark Forenciscs/LabCorp
  • Decode Genetics
  • Diadexus
  • Eiken
  • Elitech Group
  • Enzo
  • Exact Sciences
  • Fujirebio
  • Grifols
  • Hologic/Gen-Probe
  • Illumina
  • Kreatech
  • Li-Cor Biosciences
  • Monogram Biosciences/LabCorp
  • Myriad Genetics
  • Ortho-Clinical Diagnostics
  • Perkin Elmer/Caliper
  • Proteome Sciences
  • Qiagen
  • Roche
  • Scienion

For more information visit http://www.researchandmarkets.com/research/vbd2sd/2015_global

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.